Jana Rathouska

655 total citations
26 papers, 534 citations indexed

About

Jana Rathouska is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Immunology. According to data from OpenAlex, Jana Rathouska has authored 26 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Physiology and 7 papers in Immunology. Recurrent topics in Jana Rathouska's work include Hormonal Regulation and Hypertension (9 papers), Nitric Oxide and Endothelin Effects (7 papers) and Eicosanoids and Hypertension Pharmacology (4 papers). Jana Rathouska is often cited by papers focused on Hormonal Regulation and Hypertension (9 papers), Nitric Oxide and Endothelin Effects (7 papers) and Eicosanoids and Hypertension Pharmacology (4 papers). Jana Rathouska collaborates with scholars based in Czechia, Spain and Australia. Jana Rathouska's co-authors include Petr Nachtigal, Ivana Němečková, Amirhossein Sahebkar, Rudolf Štětina, Dana Hrnčiariková, Z Zadák, Radomı́r Hyšpler, Miloslav Hronek, Alena Tichá and Carmelo Bernabéu and has published in prestigious journals such as PLoS ONE, Scientific Reports and The FASEB Journal.

In The Last Decade

Jana Rathouska

23 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jana Rathouska Czechia 14 146 111 103 95 87 26 534
Kim Ramil C. Montaniel United States 7 126 0.9× 141 1.3× 86 0.8× 96 1.0× 180 2.1× 10 596
Danielle L. Michell United States 15 353 2.4× 124 1.1× 111 1.1× 96 1.0× 113 1.3× 29 741
Kerstin Wassmann Germany 12 282 1.9× 86 0.8× 147 1.4× 163 1.7× 143 1.6× 13 760
Volkan Sözer Türkiye 14 165 1.1× 73 0.7× 53 0.5× 145 1.5× 75 0.9× 35 540
Anna Konior Poland 7 165 1.1× 207 1.9× 87 0.8× 188 2.0× 154 1.8× 9 681
Morihiko Maeda Japan 9 128 0.9× 69 0.6× 79 0.8× 205 2.2× 104 1.2× 10 532
Randa H. Mohamed Egypt 17 216 1.5× 82 0.7× 94 0.9× 75 0.8× 146 1.7× 42 732
Aya Shiraki Japan 8 168 1.2× 88 0.8× 215 2.1× 84 0.9× 83 1.0× 16 513
Xiaoping Shen United States 11 282 1.9× 153 1.4× 162 1.6× 90 0.9× 70 0.8× 22 816

Countries citing papers authored by Jana Rathouska

Since Specialization
Citations

This map shows the geographic impact of Jana Rathouska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jana Rathouska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jana Rathouska more than expected).

Fields of papers citing papers by Jana Rathouska

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jana Rathouska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jana Rathouska. The network helps show where Jana Rathouska may publish in the future.

Co-authorship network of co-authors of Jana Rathouska

This figure shows the co-authorship network connecting the top 25 collaborators of Jana Rathouska. A scholar is included among the top collaborators of Jana Rathouska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jana Rathouska. Jana Rathouska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rathouska, Jana, Ivana Němečková, Radim Havelek, et al.. (2025). Anti-Endoglin monoclonal antibody prevents the progression of liver sinusoidal endothelial inflammation and fibrosis in MASH. Life Sciences. 364. 123428–123428.
2.
Rathouska, Jana, et al.. (2025). Soluble endoglin reflects endothelial dysfunction in myocardial infarction patients: a retrospective observational study. International Journal of Medical Sciences. 22(13). 3220–3228.
3.
Bláha, V., Jana Rathouska, H Langrová, et al.. (2024). Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration. Scientific Reports. 14(1). 28902–28902. 1 indexed citations
4.
Němečková, Ivana, Jana Rathouska, Jan Šilhavý, et al.. (2024). Transgenic human C-reactive protein affects oxidative stress but not inflammation biomarkers in the aorta of spontaneously hypertensive rats. BMC Cardiovascular Disorders. 24(1). 211–211. 2 indexed citations
5.
Rathouska, Jana, et al.. (2023). Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(3). 166990–166990. 2 indexed citations
6.
Němečková, Ivana, et al.. (2022). Liver fibrosis development affects tissue and soluble endoglin in mice. Atherosclerosis. 355. 45–45.
7.
Rathouska, Jana, Eva Doleželová, Ivana Němečková, et al.. (2017). High soluble endoglin levels do not induce changes in structural parameters of mouse heart. Heart and Vessels. 32(8). 1013–1024. 5 indexed citations
8.
Gallardo‐Vara, Eunate, Eva Doleželová, Jana Rathouska, et al.. (2017). Soluble endoglin modulates the pro-inflammatory mediators NF-κB and IL-6 in cultured human endothelial cells. Life Sciences. 175. 52–60. 35 indexed citations
9.
Rathouska, Jana, Ivana Němečková, Eva Doleželová, et al.. (2016). High Levels of Soluble Endoglin Induce a Proinflammatory and Oxidative-Stress Phenotype Associated with Preserved NO-Dependent Vasodilatation in Aortas from Mice Fed a High-Fat Diet. Journal of Vascular Research. 53(3-4). 149–162. 21 indexed citations
10.
Němečková, Ivana, Jana Rathouska, Carmelo Bernabéu, et al.. (2015). High Soluble Endoglin Levels Do Not Induce Endothelial Dysfunction in Mouse Aorta. PLoS ONE. 10(3). e0119665–e0119665. 20 indexed citations
11.
Sahebkar, Amirhossein, Jana Rathouska, Giuseppe Derosa, Pamela Maffioli, & Petr Nachtigal. (2015). Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmunity Reviews. 15(4). 344–353. 43 indexed citations
12.
Sahebkar, Amirhossein, Jana Rathouska, Luis E. Simental‐Mendía, & Petr Nachtigal. (2015). Statin therapy and plasma cortisol concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological Research. 103. 17–25. 29 indexed citations
13.
Rathouska, Jana, et al.. (2015). Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 243(2). 383–388. 51 indexed citations
14.
Rathouska, Jana, et al.. (2015). Endoglin is not expressed with cell adhesion molecules in aorta during atherogenesis in apoE-deficient mice.. PubMed. 30(2). 233–44. 1 indexed citations
15.
Němečková, Ivana, Jana Rathouska, Ronald J. Wong, et al.. (2013). Spirulina platensis and phycocyanobilin activate atheroprotective heme oxygenase-1: a possible implication for atherogenesis. Food & Function. 4(11). 1586–1586. 68 indexed citations
16.
Nachtigal, Petr, et al.. (2012). The role of endoglin in atherosclerosis. Atherosclerosis. 224(1). 4–11. 41 indexed citations
17.
Rathouska, Jana, et al.. (2011). Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacological Research. 64(1). 53–59. 17 indexed citations
18.
Rathouska, Jana, et al.. (2011). Activation of TGF-β Receptors and Smad Proteins by Atorvastatin is Related to Reduced Atherogenesis in ApoE/LDLR Double Knockout Mice. Journal of Atherosclerosis and Thrombosis. 19(2). 115–126. 12 indexed citations
19.
Zadák, Z, Radomı́r Hyšpler, Alena Tichá, et al.. (2009). Antioxidants and vitamins in clinical conditions. Physiological Research. 58 Suppl 1. S13–S17. 90 indexed citations
20.
Rathouska, Jana, et al.. (1993). Anticonvulsant activity of flumazenil in rats during ontogenetic development. Pharmacology Biochemistry and Behavior. 44(3). 581–586. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kim Ramil C. Montaniel Breakdown of academic impact, for papers by Danielle L. Michell Breakdown of academic impact, for papers by Kerstin Wassmann Breakdown of academic impact, for papers by Volkan Sözer Breakdown of academic impact, for papers by Anna Konior Breakdown of academic impact, for papers by Morihiko Maeda Breakdown of academic impact, for papers by Randa H. Mohamed Breakdown of academic impact, for papers by Aya Shiraki Breakdown of academic impact, for papers by Xiaoping Shen
Rankless by CCL
2026